The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension
References (10)
- et al.
Glaucoma
- et al.
New development in the drug treatment of glaucoma
Drugs
(1991) - et al.
A study of the in vitro inhibition of carbonic anhydrase isoenzymes I, II and IV
Invest Ophthalmol Visual Sci
(1993) - et al.
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor
Arch Ophthalmol
(1992)
There are more references available in the full text version of this article.
Cited by (31)
Simultaneous quantification of carteolol and dorzolamide in rabbit aqueous humor and ciliary body by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry
2010, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCarbonic anhydrase inhibitors
2009, Becker-Shaffer's Diagnosis and Therapy of the Glaucomas: Eighth EditionPharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors
2000, Progress in Retinal and Eye ResearchCitation Excerpt :After 1 week of adjunctive therapy, the mean percentage change from the end of monotherapy with dorzolamide was 20% at peak and 16% at afternoon trough. The corresponding percentage reductions from baseline were 34 and 28% (Hartenbaum, 1996). The frequency of dosing with timolol has been reduced from twice daily to once daily by incorporating the drug in a gellan gum vehicle (Laurence et al., 1993), an anionic heteropolysaccharide that forms a clear gel in the presence of cations (Rozier et al., 1989).
Carbonic anhydrase inhibitors - Part 49: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I
1998, European Journal of Medicinal ChemistryProstaglandin analogues: current treatment option for glaucoma
2016, Medicinal Chemistry Research
Copyright © 1996 Published by Elsevier Inc.